Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
BUSINESS
Alecensa Filed for Adjuvant Therapy for ALK-Positive NSCLC: Chugai
Chugai Pharmaceutical said on December 15 that it has filed its ALK inhibitor Alecensa (alectinib) for an additional indication of postoperative adjuvant therapy for ALK fusion gene-positive non-small cell lung cancer (NSCLC).The Roche group company is seeking an orphan designation…
To read the full story
Related Article
BUSINESS
- J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
November 12, 2025
- Japan Ethical Drug Sales Jump 9.7% in September: Crecon
November 11, 2025
- Kaken’s KP-001 Hits Goal in PIII Vascular Malformation Trial
November 11, 2025
- MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
- J&J Files Oral Psoriasis Drug Icotrokinra in Japan
November 10, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…